|21||Not yet recruiting||
Dynamic Hormone Diagnostics in Endocrine Disease
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
† Study has passed its completion date and status has not been verified in more than two years.